Ardsley Advisory Partners acquired a new stake in shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $305,000.

Several other large investors have also bought and sold shares of EIGR. DRW Securities LLC bought a new position in shares of Eiger Biopharmaceuticals during the 1st quarter valued at about $158,000. Bank of New York Mellon Corp boosted its position in shares of Eiger Biopharmaceuticals by 36.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 20,412 shares of the biotechnology company’s stock valued at $249,000 after purchasing an additional 5,492 shares in the last quarter. Algert Global LLC bought a new position in shares of Eiger Biopharmaceuticals during the 2nd quarter valued at about $277,000. Northern Trust Corp boosted its position in shares of Eiger Biopharmaceuticals by 169.7% during the 1st quarter. Northern Trust Corp now owns 29,376 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 18,483 shares in the last quarter. Finally, Knott David M boosted its position in shares of Eiger Biopharmaceuticals by 181.2% during the 1st quarter. Knott David M now owns 61,857 shares of the biotechnology company’s stock valued at $609,000 after purchasing an additional 39,857 shares in the last quarter. Institutional investors own 69.28% of the company’s stock.

Several research firms have recently weighed in on EIGR. BTIG Research raised their price objective on shares of Eiger Biopharmaceuticals from $23.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, May 17th. Wedbush set a $53.00 price objective on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research report on Monday. Piper Jaffray Companies restated an “overweight” rating and set a $24.00 price objective on shares of Eiger Biopharmaceuticals in a research report on Wednesday, May 30th. Zacks Investment Research lowered shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 22nd. Finally, ValuEngine lowered shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 14th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $30.75.

Shares of EIGR opened at $12.00 on Thursday. Eiger Biopharmaceuticals Inc has a one year low of $7.46 and a one year high of $18.00. The stock has a market capitalization of $175.20 million, a price-to-earnings ratio of -2.49 and a beta of 1.79. The company has a quick ratio of 8.49, a current ratio of 8.49 and a debt-to-equity ratio of 0.35.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Friday, August 10th. The biotechnology company reported ($0.82) EPS for the quarter, hitting the consensus estimate of ($0.82). analysts anticipate that Eiger Biopharmaceuticals Inc will post -3.19 earnings per share for the current fiscal year.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: Diversification For Individual Investors

Want to see what other hedge funds are holding EIGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR).

Institutional Ownership by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.